Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment

Journal of Biomedical Materials Research - Part A

Volumn 103, Issue 10, 2015, Pages 3148-3156

  Varshochian, Reyhaneh ^a   Riazi Esfahani, Mohammad ^b   Jeddi Tehrani, Mahmood ^c   Mahmoudi, Ahmad Reza ^c   Aghazadeh, Sara ^b   Mahbod, Mirgholamreza ^d   Movassat, Morteza ^b   Atyabi, Fatemeh ^a   Sabzevari, Araz ^a   Dinarvand, Rassoul ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c AVICENNA RESEARCH INSTITUTE   (Iran)

^d NOOR EYE HOSPITAL   (Iran)

Author keywords

albuminated PLGA nanoparticles; bevacizumab; choroidal neovascularization; controlled release; intraocular pharmacokinetic

Indexed keywords

EMULSIFICATION; HISTOLOGY; NANOPARTICLES; PHARMACOKINETICS; TISSUE;

BEVACIZUMAB; CHOROIDAL NEOVASCULARIZATION; CONTROLLED RELEASE; INTRAOCULAR; PLGA NANOPARTICLES;

CONTROLLED DRUG DELIVERY;

BEVACIZUMAB; NANOPARTICLE; POLYGLACTIN; ALBUMINOID; DELAYED RELEASE FORMULATION; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ALBINO RABBIT; ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG RELEASE; ELIMINATION HALF-LIFE; EYE DISEASE; EYE TOXICITY; FLUORESCENCE; MEAN RESIDENCE TIME; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; POLYMERIZATION; SUSTAINED RELEASE FORMULATION; VITREOUS BODY; ZETA POTENTIAL; ANIMAL; CHEMISTRY; CHOROIDAL NEOVASCULARIZATION; DELAYED RELEASE FORMULATION; PATHOLOGY; PHARMACOKINETICS; PHARMACOLOGY; RABBIT;

ALBUMINS; ANIMALS; BEVACIZUMAB; CHOROIDAL NEOVASCULARIZATION; DELAYED-ACTION PREPARATIONS; LACTIC ACID; NANOPARTICLES; POLYGLYCOLIC ACID; RABBITS;

EID: 84940416925     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.35446     Document Type: Article

References (38)

1. Shienbaum G, Gupta OP, Fecarotta C, Patel AH, Kaiser RS, Regillo CD,. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: Clinical andeconomic impact. Am J Ophthalmol 2012; 153: 468-73.e1.
2. Cheng SF, Dastjerdi MH, Ferrari G, Okanobo A, Bower KS, Ryan DS, Amparo F, Stevenson W, Hamrah P, Nallasamy N, Dana R,. Short-term topical bevacizumab in the treatment of stable corneal neovascularization. Am J Ophthalmol 2012; 154: 940-48.e1.
3. Dinga X, Patela M, Chana C,. Molecular pathology of age-related macular degeneration. Prog Retin Eye Res 2009; 28: 1-18.
4. Dorrell M, Uusitalo-Jarvinen H, Aguilar E, Friedlander M,. Ocular neovascularization: Basic mechanisms and therapeutic advances. Surv Ophthalmol 2007; 52(Suppl1): S3-S19.
5. Peiretti E, Vinci M, Fossarello M,. Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary tomyopia: 4-year study results. Can J Ophthalmol 2012; 47: 28-33.
6. Cionni DA, Lewis SA, Petersen MR, Foster RE, Riemann CD, Sisk RA, Hutchins RK, Miller DM,. Analysis of outcomes for intravitreal bevacizumab in the treatment of choroidal neovascularization secondary to ocular histoplasmosis. Ophthalmology 2012; 119: 327-332.
7. Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X, Tübingen Bevacizumab Study Group, Grisanti S,. Vitreous levels of bevacizumab and vascular endothelial growth factor-a in patients with choroidal neovascularization. Ophthalmology 2008; 115: 1750-1755.
8. van Wijngaarden P, Qureshi SH,. Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: A review of current practice. Clin Exp Optom 2008; 91: 427-437.
9. Achouri D, Alhanout K, Piccerelle P, Andrieu V,. Recent advances in ocular drug delivery. Drug Dev Ind Pharm 2013; 39: 1599-1617.
10. Parveen S, Misra R, Sahoo SK,. Nanoparticles: A boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine 2012; 8: 147-166.
11. Makadia HK, Siegel SJ,. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 2011; 3: 1377-1397.
12. Semete B, Booysen L, Lemmer Y, Kalombo L, Katata L, Verschoor J, Swai HS,. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine 2010; 6: 662-671.
13. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V,. PLGA-based nanoparticles: An overview of biomedical applications. J Control Release 2012; 161: 505-522.
14. Bilati U, Alle 'mann E, Doelker E,. Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles. Eur J Pharm Biopharm 2005; 59: 375-388.
15. He J, Feng M, Zhou X, Ma S, Jiang Y, Wang Y, Zhang H,. Stabilization and encapsulation of recombinant human erythropoietin into PLGA microspheres using human serum albumin as a stabilizer. Int J Pharm 2011; 416: 69-76.
16. van de Weert M, Hennink WE, Jiskoot W,. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res 2000; 17: 1159-1167.
17. Varshochian R, Jeddi-Tehrani M, Mahmoudi AR, Khoshayand MR, Atyabi F, Sabzevari A, Esfahani MR, Dinarvand R,. The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments. Eur J Pharm Sci 2013; 50: 341-352.
18. Sebak S, Mirzaei M, Malhotra M, Kulamarva A, Prakash S,. Human serum albumin nanoparticles as an efficiennoscapine drug delivery system for potential use in breast cancer: Preparation and in vitro analysis. Int J Nanomed 2010; 5: 525-532.
19. Shargel L, Wu-Pong S, Yu ABC., Applied Biopharmaceutics and Pharmacokinetics, 5th ed. New York: Appleton & Lange Reviews/McGraw-Hill, Medical Pub. Division; 2005. p 170-171.
20. Pan CK, Durairaj C, Kompella UB, Agwu O, Oliver SC, Quiroz-Mercado H, Mandava N, Olson JL,. Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model. J Ocul Pharmacol Ther 2011; 27: 219-224.
21. Li F, Hurley B, Liu Y, Leonard B, Griffith M,. Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration. Open Ophthalmol J 2012; 6: 54-58.
22. Abrishami M, Zarei-Ghanavati S, Soroush D, Rouhbakhsh M, Jaafari MR, Malaekeh- Nikouei B,. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration. Retina 2009; 29: 699-703.
23. Lu Y, Zhou N, Huang X, Cheng JW, Li FQ, Wei RL, Cai JP,. Effect ofintravitreal injection of bevacizumab-chitosan nanoparticles on retina of diabetic rats. Int J Ophtalmol 2014; 7: 1-7.
24. Andrew JS, Anglin EJ, Wu EC, Chen MY, Cheng L, Freeman WR, Sailor MJ,. Sustained release of a monoclonal antibody from electrochemically prepared mesoporous silicon oxide. Adv Funct Mater 2010; 20: 4168-4174.
25. Xu X, Weng Y, Xu L, Chen H,. Sustained release of Avastin® from polysaccharides crosslinked hydrogels for ocular drug delivery. Int J Biol Macromol 2013; 60: 272-276.
26. Wang CH, Hwang YS, Chiang PR, Shen CR, Hong WH, Hsiue GH,. Extended release of bevacizumab by thermosensitive biodegradable and biocompatible hydrogel. Biomacromolecules 2012; 13: 40-48.
27. Rauck BM, Friberg TR, Medina Mendez CA, Park D, Shah V, Bilonick RA, Wang Y,. Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo. Invest Ophthalmol Vis Sci 2014; 55: 469-476.
28. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ,. Pharmacokinetics of intravitreal bevacizumab (avastin). Ophthalmology 2007; 114: 855-859.
29. Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, Shinomiya K, Nugent AK, Hirooka K, Baba T,. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009; 50: 4807-4813.
30. Krohne TU, Eter N, Holz FG, Meyer CH,. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008; 146: 508-512.
31. El Sanharawi M, Kowalczuk L, Touchard E, Omri S, de Kozak Y, Behar-Cohen F., Protein delivery for retinal diseases: From basic considerations to clinical applications. Prog Retin Eye Res 2010; 29: 443-465.
32. Hamidi M, Azadi A, Rafiei P, Ashrafi H,. A pharmacokinetic overview of nanotechnology-based drug delivery systems: An ADME-oriented approach. Crit Rev Ther Drug Carrier Syst 2013; 30: 435-467.
33. Wang Y, Fei D, Vanderlaan M, Song A,. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004; 7: 335-345.
34. Yang R, Shim WS, Cui FD, Cheng G, Han X, Jin QR, Kim DD, Chung SJ, Shim CK,. Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor. Int J Pharm 2009; 371: 142-147.
35. Tomoda K, Watanabe A, Suzuki K, Inagi T, Terada H, Makino K,. Enhanced transdermal permeability of estradiol using combination of PLGA nanoparticles system and iontophoresis. Colloids Surf B Biointerfaces 2012; 97: 84-89.
36. Hirota K, Kawamoto T, Nakajima T, Makino K, Terada H,. Distribution and deposition of respirable PLGA microspheres in lung alveoli. Colloids Surf B Biointerfaces 2013; 105: 92-97.
37. Yasukawa T, Ogura Y, Tabata Y, Kimura H, Wiedemann P, Honda Y,. Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res 2004; 23: 253-281.
38. Sakurai E, Ozeki H, Kunou N, Ogura Y,. Effect of particle size of polymeric nanospheres on intravitreal kinetics. Ophthalmic Res 2001; 33: 31-36.